

Domestic approval of an anti-HIV drug, Stribild(R) Combination Tablets


Senior Assistant Professor Eiichi Kodama

Senior Assistant Professor Eiichi Kodama of Tohoku University Graduate School of Medicine, Miyagi Area Medical Support Endowed Chair (Concurrently: Tohoku Medical Megabank Organization ToMMo Clinical Fellow, Department of Comprehensive Infection Tohoku University Hospital) during his tenure at Kyoto University jointly developed with Japan Tobacco Inc. (JT) an anti-HIV drug (Elvitegravir : HIV integrase inhibitor) which is included in Stribild(R) Combination Tablets (Gilead Sciences, Inc. NDA). Following its approval by U.S. Food and Drug Administration in August 2012, this drug received an approval of production and marketing in Japan, which is now to be sold from Torii Pharmaceutical Co., Ltd. after National Health Insurance price listing.



Senior Assistant Professor
KODAMA, Eiichi
Comprehensive Infection
kodama515@med.tohoku.ac.jp
<http://seiryorb.t.xsrv.jp/>

A



B



Model of elvitegravir (yellow) in the integrase and representative amino acids (A) and Stribild combination tablets (B).

Shimura K, and Kodama E. *Antiviral Chem Chemother* 20:79-85, 2009

Shimura K, et al. *J Virol* 82: 764-774, 2008

Sato M, et al., *J Med Chem* 49:1506-8, 2006